RSV, respiratory syncytial virus, usually peaks in December and January while infecting the nose, throat and lungs, usually ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

Nirsevimab is protective against RSV infections and coinfections, which suggests there is no replacement of RSV with other viruses post-nirsevimab administration.

US-based Inhalon Biopharma is set to launch a trial of its at-home nebulised treatment for respiratory syncytial virus (RSV) ...

With a recent surge in influenza, COVID-19, norovirus, respiratory syncytial virus (RSV), and other respiratory viruses, it's ...

Respiratory syncytial virus (RSV) leads to over 30 million severe respiratory infections, 3.5 million hospitalizations, and 100,000 deaths among children under five each year globally. Nearly half of ...

The virus is a common respiratory illness that infects the lungs and airways. Most people experience mild symptoms, like the common cold. However, RSV can cause more severe symptoms in infants, older ...

From today, February 3, pregnant women in Australia will be eligible for a free RSV vaccine under the National Immunisation ...

RSV is a common virus that affects the lungs and breathing passages, and here are some steps you can take to protect yourself ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.